Health Canada has approved Keytruda (pembrolizumab), for the first-line treatment, as monotherapy, for adult patients with metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer.
More than a year after a catastrophic shortage of platinum-based chemotherapy drugs swept through the U.S., FDA on June 28 officially removed carboplatin and cisplatin from the drug shortage list.
